Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.69 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.69 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.69 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.69 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.69 |
| ▸ | DHODH | Q02127 | 7/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618008 | 1.00 | GABRA1 (0.69) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8535314 | 0.88 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8586468 | 0.86 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8534202 | 0.86 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8581797 | 0.85 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8534161 | 0.83 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2652800 | 0.82 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29899479 | 0.82 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6121572 | 0.82 | GABRA1 (0.69) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8534623 | 0.82 | GABRA1 (0.65) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388176-B2 | Method of treating conditiions with kinase inhibitors | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | claimed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-3555100-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237530-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068161-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | GABRA1 5/4885GABRG2 20/4885GABRB3 8/4885 |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | GABRA1 39/4885GABRG2 52/4885GABRB3 62/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRA1 5/4885GABRG2 24/4885GABRB3 15/4885 |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRA1 5/4885GABRG2 22/4885GABRB3 16/4885 |
| US-20130237530-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GABRA3, GABRB3 | GABRA1 6/4885GABRG2 12/4885GABRB3 3/4885 |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | GABRA1 3/4885GABRG2 14/4885GABRB3 11/4885 |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | GABRA1 3/4885GABRG2 14/4885GABRB3 11/4885 |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | GABRA1 3/4885GABRG2 13/4885GABRB3 10/4885 |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GRM1 | GABRA1 5/4885GABRG2 25/4885GABRB3 17/4885 |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | CDK5, MAP3K1, ALDH1A2 | GABRA1 3023/4885GABRG2 2641/4885GABRB3 2187/4885 |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRB1 | GABRA1 6/4885GABRG2 20/4885GABRB3 7/4885 |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRA1 5/4885GABRG2 20/4885GABRB3 15/4885 |
| US-20130237538-A1 | KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K2 | GABRA1 3064/4885GABRG2 2308/4885GABRB3 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.